Dysthymia (persistent depressive disorder): symptoms and treatment | Clinique Omicron<\/title>\n<meta name=\"description\" content=\"Dysthymia or persistent depressive disorder is chronic low-grade depression lasting more than 2 years. DSM-5 criteria, antidepressants, psychotherapy and management in Quebec.\">\n<meta name=\"keywords\" content=\"dysthymie traitement, trouble d\u00e9pressif persistant, dysthymie sympt\u00f4mes, dysthymie antid\u00e9presseurs, d\u00e9pression chronique traitement, dysthymie diagnostic DSM-5, double d\u00e9pression, dysthymie psychoth\u00e9rapie\">\n<link rel=\"preconnect\" href=\"https:\/\/fonts.googleapis.com\">\n<link href=\"https:\/\/fonts.googleapis.com\/css2?family=Cinzel:wght@600&family=Poppins:wght@400;500;600;700&display=swap\" rel=\"stylesheet\">\n<style>\n.co-wrap * { font-family: 'Poppins', sans-serif; box-sizing: border-box; }\n.co-wrap { max-width: 1100px; margin: 0 auto; padding: 30px 0 60px; }\n.co-label { font-family: 'Cinzel', serif; font-size: 14px; font-weight: bold; letter-spacing: 1px; text-transform: uppercase; color: #4D6577; margin-bottom: 14px; display: block; }\n.co-wrap h1 { font-size: 32px; font-weight: 500; color: #323C52; margin: 0 0 22px; line-height: 1.2; }\n.co-intro { font-size: 16px; line-height: 1.75; color: #4D6577; margin-bottom: 36px; padding-bottom: 32px; border-bottom: 1px solid rgba(77,101,119,.2); }\n.co-wrap h2 { font-size: 20px; font-weight: 600; color: #323C52; margin: 32px 0 12px; }\n.co-wrap p { font-size: 15px; color: #4D6577; line-height: 1.7; margin-bottom: 14px; }\n.co-list { list-style: none; padding: 0; margin: 12px 0 24px; }\n.co-list li { font-size: 15px; color: #4D6577; padding: 10px 14px 10px 38px; margin-bottom: 8px; border-radius: 6px; position: relative; background: rgba(77,101,119,.06); border-left: 3px solid #4D6577; }\n.co-list li::before { content: \"\u2713\"; position: absolute; left: 12px; font-weight: 700; color: #4D6577; }\n.co-table { width: 100%; border-collapse: collapse; margin: 14px 0 22px; font-size: 14px; border-radius: 8px; overflow: hidden; table-layout: fixed; }\n.co-table thead tr { background: #323C52; color: #fff; }\n.co-table thead th { padding: 11px 16px; text-align: left; font-weight: 600; font-size: 13px; }\n.co-table tbody tr:nth-child(even) { background: rgba(77,101,119,.06); }\n.co-table tbody tr:nth-child(odd) { background: #fff; }\n.co-table td { padding: 10px 16px; color: #4D6577; border-bottom: 1px solid rgba(77,101,119,.12); font-size: 14px; vertical-align: top; }\n.co-table td:first-child { font-weight: 600; color: #323C52; }\n.co-infobox { display: flex; gap: 12px; background: rgba(77,101,119,.06); border-radius: 8px; border-left: 4px solid #4D6577; padding: 14px 18px; margin: 18px 0 28px; font-size: 14px; color: #4D6577; line-height: 1.65; }\n.co-infobox .ico { font-size: 18px; flex-shrink: 0; }\n.co-urgence { background: #fff8f8; border-left: 5px solid #c0392b; border-radius: 6px; padding: 20px 26px; margin: 24px 0 32px; }\n.co-urgence .co-urgence-titre { font-size: 13px; font-weight: 700; color: #c0392b; letter-spacing: 1.5px; text-transform: uppercase; margin-bottom: 10px; }\n.co-urgence p { color: #5a2020; font-size: 14px; margin: 0 0 10px; line-height: 1.7; }\n.co-urgence p:last-child { margin-bottom: 0; }\n.co-disclaimer { font-size: 13px; color: #8a9aaa; font-style: italic; border-top: 1px solid rgba(77,101,119,.15); padding-top: 24px; margin-top: 40px; line-height: 1.6; }\n<\/style>\n<\/head>\n<body>\n<div class=\"co-wrap\">\n <span class=\"co-label\">Psychiatry & Psychology & Family Medicine<\/span>\n <h1>Dysthymia (persistent depressive disorder)<\/h1>\n\n <div class=\"co-intro\">\n Dysthymia - officially renamed <strong>persistent depressive disorder (PDD)<\/strong> in DSM-5 (2013) and ICD-11 (2022) - is a mood disorder characterized by chronic low-grade depressed mood, present most of the time for at least two consecutive years in adults (and at least one year in children and adolescents), without fulfilling all the criteria for a characterized depressive episode (CDE) for the entire duration. Unlike major depression - whose episodes are typically more intense, more circumscribed in time and with remissions between episodes - dysthymia is insidious, persistent and often experienced by the patient as part of their personality or character (\u00abI'm a naturally sad person\u00bb), which often delays diagnosis by several years. Its lifetime prevalence is estimated at 3-6 % of the general population, with an annual prevalence of 1.5-3 % - dysthymia is diagnosed around twice as often in women as in men. Age of onset varies: an early-onset form (before age 21) is distinguished from a late-onset form (after age 21) - the early form is associated with greater psychiatric comorbidity, a more prolonged course and a poorer functional prognosis. Dysthymia leads to significant functional impairment - comparable to or even greater than that of major depressive episodes in some longitudinal studies - affecting interpersonal relationships, work performance and overall quality of life. It is frequently associated with psychiatric comorbidities (anxiety disorder in 40-70 % of cases, personality disorder in 20-40 %, substance abuse in 15-25 %) and medical conditions (cardiovascular disease, type 2 diabetes, chronic pain). The concept of <strong>double depression<\/strong> - superimposing an EDC on a pre-existing dysthymia - is observed in 40-75 % of dysthymic patients over their lifetime, and is associated with increased clinical severity, poorer response to treatment and higher risk of recurrence.\n <\/div>\n\n <h2>Diagnostic criteria and clinical presentation<\/h2>\n <ul class=\"co-list\">\n <li><strong>Criterion A (DSM-5) :<\/strong> depressed mood present most of the time, almost every day, for at least 2 consecutive years (adults) or 1 year (children\/adolescents) - reported by the patient or observed by family and friends; periods without depressed mood do not exceed 2 consecutive months within 2 years<\/li>\n <li><strong>Criterion B (DSM-5) - at least 2 of the following 6 symptoms:<\/strong> decreased or increased appetite; insomnia or hypersomnia; low energy or chronic fatigue; low self-esteem; difficulty concentrating or making decisions; hopelessness - a feeling that things will never get better<\/li>\n <li><strong>Exclusion criteria :<\/strong> absence of EDC during the first 2 years (if EDC present \u2192 double depression); absence of manic, hypomanic or cyclothymic episode (\u2192 bipolar disorder); absence of schizoaffective or psychotic disorder; absence of effects of a substance or medical condition (hypothyroidism, Cushing's, anemia, neurological diseases)<\/li>\n <li><strong>Typical clinical profile :<\/strong> chronic \u00abgray\u00bb mood (sadness, emotional emptiness, partial anhedonia - unlike EDC, where the anhedonia is total), chronic pessimism, feelings of personal inefficiency, excessive self-criticism, persistent fatigability, progressive social withdrawal, irritability (especially in children\/adolescents); the patient often reports \u00abnever having been well\u00bb or \u00abremembering always having been like this since adolescence\u00bb.\u00bb<\/li>\n <li><strong>DSM-5 specifications :<\/strong> with early onset (<21 years) or late onset (\u226521 years); with concomitant anxiety; with mixed distress; with melancholic features (profound anhedonia, excessive guilt, early morning awakening, diurnal variation); with atypical features (hypersomnolence, hyperphagia, sensitivity to rejection)<\/li>\n <\/ul>\n\n <h2>Differential diagnosis and workup<\/h2>\n <ul class=\"co-list\">\n <li><strong>Major depression (EDC):<\/strong> higher intensity and number of symptoms (5\/9 criteria required), duration \u22652 weeks per episode but episodic course with remissions - distinction is sometimes difficult if EDC is mild and chronic; in case of doubt: treat as dysthymia and reassess<\/li>\n <li><strong>Bipolar disorder II :<\/strong> major depressive episodes + hypomanic episodes (\u22654 days) - always check for a history of hypomania and bipolar family history before starting an antidepressant alone (risk of manic drift); use the MDQ (Mood Disorder Questionnaire) for screening purposes<\/li>\n <li><strong>Medical causes to be systematically excluded:<\/strong> TSH (hypothyroidism); CBC + ferritin (iron-deficiency anemia); blood glucose + HbA1c (diabetes); liver function tests (chronic hepatitis C); vitamin D 25-OH; 24h urinary cortisol or dexamethasone braking (Cushing's disease); blood calcium (hyperparathyroidism); total testosterone in men (hypogonadism).<\/li>\n <li><strong>Personality disorder:<\/strong> chronic depressive features may be difficult to distinguish from borderline (emotional instability), avoidant (social withdrawal) or depressive disorder (constitutional pessimism) - frequent comorbidity (20-40 % of dysthymics); in-depth psychological assessment is sometimes required<\/li>\n <li><strong>Assessment tools :<\/strong> PHQ-9 (score \u226510 = moderate to severe depression - sensitivity 88 % for EDC); PHQ-2 (rapid screening 2 items); MDQ (bipolar screening); GAD-7 (very frequent comorbid anxiety); Cornell scale (elderly)<\/li>\n <\/ul>\n\n <h2>Treatments<\/h2>\n <table class=\"co-table\">\n <colgroup><col style=\"width:200px;\"><col style=\"width:42%;\"><col><\/colgroup>\n <thead>\n <tr><th>Treatment<\/th><th>Mechanism, dosage and indication<\/th><th>Effectiveness, duration and precautions<\/th><\/tr>\n <\/thead>\n <tbody>\n <tr>\n <td>SSRIS<br><small style=\"font-weight:400;color:#7a8fa0;\">1st-line pharmacology<\/small><\/td>\n <td>Serotonin transporter (SERT) blockade \u2192 increased synaptic availability of 5-HT \u2192 progressive neuroplastic effects (BDNF - HPA axis); sertraline (Zoloft) 50 mg\/day \u2192 100-200 mg\/day: 1st line recommended (favorable CYP interaction profile); escitalopram (Cipralex) 10 mg\/day \u2192 20 mg\/day : well tolerated, low CYP interactions; fluoxetine (Prozac) 20 mg\/day \u2192 40-60 mg\/day: long half-life (14 days for norfluoxetine \u2192 advantage if irregular adherence); paroxetine 20-40 mg\/day: effective but anticholinergic + CYP2D6 inhibitor; citalopram 20-40 mg\/day: limit to 40 mg\/d (QTc) - 20 mg\/d if >60 years old<\/td>\n <td>Onset of action: 2-4 weeks for first effects, 6-8 weeks for full effect - explain this delay to the patient to prevent early discontinuation; NNT \u2248 4.5 for response vs placebo (Lima 2003 meta-analysis - Cochrane); minimum recommended duration: 2 years (CANMAT 2016) due to chronic nature; sexual dysfunction 30-40 % (inform patient); withdrawal syndrome on discontinuation (especially paroxetine) \u2192 mandatory gradual taper over \u22654 weeks<\/td>\n <\/tr>\n <tr>\n <td>IRSNa<br><small style=\"font-weight:400;color:#7a8fa0;\">1st line - anxiety or pain comorbidity<\/small><\/td>\n <td>SERT + NET (noradrenaline) blockade \u2192 dual serotonergic + noradrenergic action; venlafaxine (Effexor XR) 37.5-75 mg\/day \u2192 150-225 mg\/day (significant noradrenergic action only >150 mg\/day); duloxetine (Cymbalta) 30 mg\/day \u2192 60-120 mg\/day : advantage if concomitant neuropathic pain or fibromyalgia (formal indication); desvenlafaxine (Pristiq) 50 mg\/day: fewer CYP2D6 interactions<\/td>\n <td>Efficacy in dysthymia comparable to SSRIs (CANMAT); blood pressure monitoring with high-dose venlafaxine (dose-dependent hypertension - monthly BP if >150 mg\/day); severe withdrawal syndrome on abrupt discontinuation of venlafaxine \u2192 decrease over several weeks mandatory; duloxetine: frequent nausea at start of treatment (take in the evening with a meal); hepatic monitoring if alcohol consumption.<\/td>\n <\/tr>\n <tr>\n <td>Psychotherapy - CBT, TIP, CBASP<br><small style=\"font-weight:400;color:#7a8fa0;\">1st line - in combination with pharmacotherapy<\/small><\/td>\n <td>CBT (cognitive-behavioural therapy): restructuring of chronic negative cognitive patterns (automatic pessimistic thoughts, cognitive distortions) + behavioural activation - 12-20 weekly sessions; IPT (interpersonal therapy): focus on chronic relationship difficulties - 16 sessions; CBASP (Cognitive Behavioral Analysis System of Psychotherapy - McCullough): psychotherapy developed specifically for chronic depression - situational analysis and interpersonal consequences - superior to standard CBT in some chronic depression trials.<\/td>\n <td>Antidepressant + psychotherapy combination superior to each modality alone in chronic depression (NNT \u2248 3.2 - Cuijpers 2010 meta-analysis - JAMA); access to psychotherapy in Quebec: significant delays in the public network (CLSC, GMF) - some GMF-U and affiliated clinics offer integrated psychology services; RAMQ reimbursement under certain PASM programs; ACT and MBCT (mindfulness): emerging data in dysthymia for reduction of ruminations and experiential avoidance<\/td>\n <\/tr>\n <tr>\n <td>2nd-line antidepressants and augmentation strategies<br><small style=\"font-weight:400;color:#7a8fa0;\">Resistance or intolerance to SSRIs\/ASNRIs<\/small><\/td>\n <td>Mirtazapine (Remeron) 15-45 mg\/day at bedtime: presynaptic \u03b12 antagonist + 5-HT2\/5-HT3 + H1 \u2192 sedation + increased appetite - useful if insomnia + weight loss + anxiety; bupropion (Wellbutrin XL) 150-300 mg\/day: NE + DA reuptake inhibitor \u2192 activating if fatigue + apathy + SSRI-induced sexual dysfunction - CI epilepsy, TCA, alcohol withdrawal; agomelatine (Valdoxan) 25-50 mg\/day: MT1\/MT2 agonist + 5-HT2C antagonist \u2192 normalization of circadian rhythm - monthly liver monitoring for first 6 months; augmentation with lithium (0.4-0.8 mmol\/L) + quetiapine XR (Seroquel 50-300 mg\/night) + aripiprazole (Abilify 5-15 mg\/day) if partial response at optimal dose<\/td>\n <td>Add-on strategy indicated if partial response after 8 weeks at optimal dose of an SSRI\/SNRI; lithium: recommendation level 1 (CANMAT 2016) - lithiaemia + TSH + creatinine + calcaemia to be monitored; quetiapine: formal indication in unipolar depression (El-Khalili 2010 meta-analysis) - metabolic monitoring (blood sugar, cholesterol, weight); aripiprazole: augmentation if partial response to DAs; ketamine\/esketamine (Spravato): reserved for resistant depression in specialized setting - not approved in pure dysthymia in Canada<\/td>\n <\/tr>\n <tr>\n <td>Healthy living and complementary interventions<br><small style=\"font-weight:400;color:#7a8fa0;\">Adjuvants - proven effectiveness<\/small><\/td>\n <td>Aerobic physical exercise: 150 min\/week of moderate intensity (brisk walking, cycling, swimming) \u2192 increase BDNF, reduce cortisol, improve prefrontal neuroplasticity - CANMAT 2016 recommendation (level 1); light therapy: 10,000 lux for 30 min in the morning \u2192 efficacy in seasonal and non-seasonal dysthymia (Lam 2016 meta-analysis - JAMA Psychiatry) - available in pharmacies or for hire; sleep hygiene: regular schedules, avoid screens before bedtime, ICT (cognitive therapy for insomnia) if associated chronic insomnia; alcohol reduction (CNS depressant - frequent self-medication but worsens dysthymia in the medium term)<\/td>\n <td>Physical exercise is often under-prescribed despite its proven efficacy (MDS -0.66 vs control - Schuch 2016 - American Journal of Psychiatry) - written prescription for physical activity (PEP) improves adherence; light therapy: relative contraindication in bipolar disorder (risk of manic turn - use cautiously with supervision); omega-3s (EPA 1-2 g\/day): modest efficacy as adjunct to pharmacotherapy (CANMAT level 2 - Grosso 2014 meta-analysis) - to be proposed if reluctant to take medication or as a supplement<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n\n <div class=\"co-infobox\">\n <span class=\"ico\">\u2139\ufe0f<\/span>\n <span>Visit <strong>double depression<\/strong> - superimposing a characterized depressive episode on a pre-existing dysthymia - is observed in 40-75 % of dysthymic people over the course of their lives. It manifests as a sudden worsening of the chronic baseline mood, with the onset of more intense symptoms (profound anhedonia, psychomotor slowing, suicidal ideation) exceeding the criteria for dysthymia alone. Double depression is associated with a less complete response to antidepressants (frequent partial remission - return to baseline dysthymic level without complete recovery) and a higher rate of recurrence. A <strong>complete remission<\/strong> (return to euthymia) must always be the therapeutic goal, and not simply a return to dysthymic levels. Long-term follow-up (\u22652 years of pharmacological treatment + psychotherapy) is essential to prevent relapse.<\/span>\n <\/div>\n\n <div class=\"co-urgence\">\n <div class=\"co-urgence-titre\">Suicidal ideation - Help available<\/div>\n <p>Although low-grade, dysthymia is associated with a significant suicidal risk - especially in the case of double depression or in the presence of co-morbidities (personality disorder, substance abuse, social isolation). If you are experiencing suicidal thoughts or thoughts of death, talk to your doctor or a mental health professional.<\/p>\n <p><strong>Quebec suicide prevention line: 1 866 APPELLE (277-3553)<\/strong> - available 24\/7; ; <strong>Crise Montr\u00e9al: 514 890-6000<\/strong> ; <strong>Kids Help Phone: 1 800 668-6868<\/strong> (under 29 years of age). In case of immediate danger to yourself: call <strong>911<\/strong> or go to the nearest emergency room.<\/p>\n <\/div>\n\n <h2>Consult at Clinique Omicron<\/h2>\n <p>Clinique Omicron's physicians provide initial screening and management of dysthymia - structured clinical evaluation (PHQ-9), workup to rule out medical causes (TSH, CBC, metabolic workup), initiation of first-line pharmacotherapy, referral to psychology or psychiatry, and longitudinal follow-up of treatment. Telemedicine is available for follow-up mental health consultations at our points of service in Quebec. To book an appointment, visit <a href=\"https:\/\/cliniqueomicron.ca\">cliniqueomicron.ca<\/a>.<\/p>\n\n <p class=\"co-disclaimer\">The content of this page is provided for informational purposes only and does not replace the advice of a qualified healthcare professional. If you experience persistent depressive symptoms, consult your physician or a mental health professional. In the event of a crisis, contact available resources immediately.<\/p>\n<\/div>\n<\/body>\n<\/html>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Dysthymie (trouble d\u00e9pressif persistant) : sympt\u00f4mes et traitement | Clinique Omicron Psychiatrie & Psychologie & M\u00e9decine de famille Dysthymie (trouble d\u00e9pressif persistant) La dysthymie \u2014 officiellement renomm\u00e9e trouble d\u00e9pressif persistant (TDP) dans le DSM-5 (2013) et la CIM-11 (2022) \u2014 est un trouble de l’humeur caract\u00e9ris\u00e9 par une humeur d\u00e9pressive chronique de bas grade, pr\u00e9sente… <a href=\"https:\/\/cliniqueomicron.ca\/en\/dysthymie\/\" rel=\"bookmark\">Read More \"<span class=\"screen-reader-text\">Dysthymia (persistent depressive disorder): symptoms and treatment | Clinique Omicron<\/span><\/a><\/p>","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"off","neve_meta_content_width":100,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"_metasync_otto_title":"Dysthymie (trouble d\u00e9pressif persistant) | Omicron","_metasync_otto_description":"Dysthymie : Clinique Omicron \u00e0 Brossard propose un traitement efficace avec psychoth\u00e9rapie et m\u00e9dicaments. Am\u00e9liorez votre quotidien. Contactez-nous.","_metasync_otto_keywords":"","_metasync_otto_og_title":"Dysthymie (trouble d\u00e9pressif | Brossard | Clinique Omicron","_metasync_otto_og_description":"La dysthymie ou trouble d\u00e9pressif persistant est une d\u00e9pression chronique de bas grade durant plus de 2 ans. Crit\u00e8res DSM-5, antid\u00e9presseurs, psychoth\u00e9rapie...","_metasync_otto_twitter_title":"Dysthymie (trouble d\u00e9pressif | Brossard | Clinique Omicron","_metasync_otto_twitter_description":"La dysthymie ou trouble d\u00e9pressif persistant est une d\u00e9pression chronique de bas grade durant plus de 2 ans. Crit\u00e8res DSM-5, antid\u00e9presseurs, psychoth\u00e9rapie...","rank_math_title":"","rank_math_description":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_aioseo_title":"Dysthymie (trouble d\u00e9pressif persistant) : sympt\u00f4mes et traitement | Clinique Omicron","_aioseo_description":"La dysthymie ou trouble d\u00e9pressif persistant est une d\u00e9pression chronique de bas grade durant plus de 2 ans. Crit\u00e8res DSM-5, antid\u00e9presseurs, psychoth\u00e9rapie et prise en charge au Qu\u00e9bec.","_metasync_seo_title":"","_metasync_seo_desc":"","_metasync_breadcrumb_title":"","_metasync_primary_category":0,"_metasync_primary_product_cat":0,"_metasync_otto_disabled":"","_metasync_hreflang":"","_metasync_plugin_sync_ts":"{\"aioseo\":\"2026-05-04T21:54:40+00:00\"}","_metasync_robots_advanced":"","footnotes":""},"class_list":["post-24524","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/pages\/24524","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/comments?post=24524"}],"version-history":[{"count":4,"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/pages\/24524\/revisions"}],"predecessor-version":[{"id":28480,"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/pages\/24524\/revisions\/28480"}],"wp:attachment":[{"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/media?parent=24524"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

\n\t\t\t\t

\n\t\t\t\t\t

\n\t\t\t\t

\n\t\t\t\t\t\n\n\n\n\nDysthymia (persistent depressive disorder): symptoms and treatment | Clinique Omicron<\/title>\n<meta name=\"description\" content=\"Dysthymia or persistent depressive disorder is chronic low-grade depression lasting more than 2 years. DSM-5 criteria, antidepressants, psychotherapy and management in Quebec.\">\n<meta name=\"keywords\" content=\"dysthymie traitement, trouble d\u00e9pressif persistant, dysthymie sympt\u00f4mes, dysthymie antid\u00e9presseurs, d\u00e9pression chronique traitement, dysthymie diagnostic DSM-5, double d\u00e9pression, dysthymie psychoth\u00e9rapie\">\n<link rel=\"preconnect\" href=\"https:\/\/fonts.googleapis.com\">\n<link href=\"https:\/\/fonts.googleapis.com\/css2?family=Cinzel:wght@600&family=Poppins:wght@400;500;600;700&display=swap\" rel=\"stylesheet\">\n<style>\n.co-wrap * { font-family: 'Poppins', sans-serif; box-sizing: border-box; }\n.co-wrap { max-width: 1100px; margin: 0 auto; padding: 30px 0 60px; }\n.co-label { font-family: 'Cinzel', serif; font-size: 14px; font-weight: bold; letter-spacing: 1px; text-transform: uppercase; color: #4D6577; margin-bottom: 14px; display: block; }\n.co-wrap h1 { font-size: 32px; font-weight: 500; color: #323C52; margin: 0 0 22px; line-height: 1.2; }\n.co-intro { font-size: 16px; line-height: 1.75; color: #4D6577; margin-bottom: 36px; padding-bottom: 32px; border-bottom: 1px solid rgba(77,101,119,.2); }\n.co-wrap h2 { font-size: 20px; font-weight: 600; color: #323C52; margin: 32px 0 12px; }\n.co-wrap p { font-size: 15px; color: #4D6577; line-height: 1.7; margin-bottom: 14px; }\n.co-list { list-style: none; padding: 0; margin: 12px 0 24px; }\n.co-list li { font-size: 15px; color: #4D6577; padding: 10px 14px 10px 38px; margin-bottom: 8px; border-radius: 6px; position: relative; background: rgba(77,101,119,.06); border-left: 3px solid #4D6577; }\n.co-list li::before { content: \"\u2713\"; position: absolute; left: 12px; font-weight: 700; color: #4D6577; }\n.co-table { width: 100%; border-collapse: collapse; margin: 14px 0 22px; font-size: 14px; border-radius: 8px; overflow: hidden; table-layout: fixed; }\n.co-table thead tr { background: #323C52; color: #fff; }\n.co-table thead th { padding: 11px 16px; text-align: left; font-weight: 600; font-size: 13px; }\n.co-table tbody tr:nth-child(even) { background: rgba(77,101,119,.06); }\n.co-table tbody tr:nth-child(odd) { background: #fff; }\n.co-table td { padding: 10px 16px; color: #4D6577; border-bottom: 1px solid rgba(77,101,119,.12); font-size: 14px; vertical-align: top; }\n.co-table td:first-child { font-weight: 600; color: #323C52; }\n.co-infobox { display: flex; gap: 12px; background: rgba(77,101,119,.06); border-radius: 8px; border-left: 4px solid #4D6577; padding: 14px 18px; margin: 18px 0 28px; font-size: 14px; color: #4D6577; line-height: 1.65; }\n.co-infobox .ico { font-size: 18px; flex-shrink: 0; }\n.co-urgence { background: #fff8f8; border-left: 5px solid #c0392b; border-radius: 6px; padding: 20px 26px; margin: 24px 0 32px; }\n.co-urgence .co-urgence-titre { font-size: 13px; font-weight: 700; color: #c0392b; letter-spacing: 1.5px; text-transform: uppercase; margin-bottom: 10px; }\n.co-urgence p { color: #5a2020; font-size: 14px; margin: 0 0 10px; line-height: 1.7; }\n.co-urgence p:last-child { margin-bottom: 0; }\n.co-disclaimer { font-size: 13px; color: #8a9aaa; font-style: italic; border-top: 1px solid rgba(77,101,119,.15); padding-top: 24px; margin-top: 40px; line-height: 1.6; }\n<\/style>\n<\/head>\n<body>\n<div class=\"co-wrap\">\n <span class=\"co-label\">Psychiatry & Psychology & Family Medicine<\/span>\n <h1>Dysthymia (persistent depressive disorder)<\/h1>\n\n <div class=\"co-intro\">\n Dysthymia - officially renamed <strong>persistent depressive disorder (PDD)<\/strong> in DSM-5 (2013) and ICD-11 (2022) - is a mood disorder characterized by chronic low-grade depressed mood, present most of the time for at least two consecutive years in adults (and at least one year in children and adolescents), without fulfilling all the criteria for a characterized depressive episode (CDE) for the entire duration. Unlike major depression - whose episodes are typically more intense, more circumscribed in time and with remissions between episodes - dysthymia is insidious, persistent and often experienced by the patient as part of their personality or character (\u00abI'm a naturally sad person\u00bb), which often delays diagnosis by several years. Its lifetime prevalence is estimated at 3-6 % of the general population, with an annual prevalence of 1.5-3 % - dysthymia is diagnosed around twice as often in women as in men. Age of onset varies: an early-onset form (before age 21) is distinguished from a late-onset form (after age 21) - the early form is associated with greater psychiatric comorbidity, a more prolonged course and a poorer functional prognosis. Dysthymia leads to significant functional impairment - comparable to or even greater than that of major depressive episodes in some longitudinal studies - affecting interpersonal relationships, work performance and overall quality of life. It is frequently associated with psychiatric comorbidities (anxiety disorder in 40-70 % of cases, personality disorder in 20-40 %, substance abuse in 15-25 %) and medical conditions (cardiovascular disease, type 2 diabetes, chronic pain). The concept of <strong>double depression<\/strong> - superimposing an EDC on a pre-existing dysthymia - is observed in 40-75 % of dysthymic patients over their lifetime, and is associated with increased clinical severity, poorer response to treatment and higher risk of recurrence.\n <\/div>\n\n <h2>Diagnostic criteria and clinical presentation<\/h2>\n <ul class=\"co-list\">\n <li><strong>Criterion A (DSM-5) :<\/strong> depressed mood present most of the time, almost every day, for at least 2 consecutive years (adults) or 1 year (children\/adolescents) - reported by the patient or observed by family and friends; periods without depressed mood do not exceed 2 consecutive months within 2 years<\/li>\n <li><strong>Criterion B (DSM-5) - at least 2 of the following 6 symptoms:<\/strong> decreased or increased appetite; insomnia or hypersomnia; low energy or chronic fatigue; low self-esteem; difficulty concentrating or making decisions; hopelessness - a feeling that things will never get better<\/li>\n <li><strong>Exclusion criteria :<\/strong> absence of EDC during the first 2 years (if EDC present \u2192 double depression); absence of manic, hypomanic or cyclothymic episode (\u2192 bipolar disorder); absence of schizoaffective or psychotic disorder; absence of effects of a substance or medical condition (hypothyroidism, Cushing's, anemia, neurological diseases)<\/li>\n <li><strong>Typical clinical profile :<\/strong> chronic \u00abgray\u00bb mood (sadness, emotional emptiness, partial anhedonia - unlike EDC, where the anhedonia is total), chronic pessimism, feelings of personal inefficiency, excessive self-criticism, persistent fatigability, progressive social withdrawal, irritability (especially in children\/adolescents); the patient often reports \u00abnever having been well\u00bb or \u00abremembering always having been like this since adolescence\u00bb.\u00bb<\/li>\n <li><strong>DSM-5 specifications :<\/strong> with early onset (<21 years) or late onset (\u226521 years); with concomitant anxiety; with mixed distress; with melancholic features (profound anhedonia, excessive guilt, early morning awakening, diurnal variation); with atypical features (hypersomnolence, hyperphagia, sensitivity to rejection)<\/li>\n <\/ul>\n\n <h2>Differential diagnosis and workup<\/h2>\n <ul class=\"co-list\">\n <li><strong>Major depression (EDC):<\/strong> higher intensity and number of symptoms (5\/9 criteria required), duration \u22652 weeks per episode but episodic course with remissions - distinction is sometimes difficult if EDC is mild and chronic; in case of doubt: treat as dysthymia and reassess<\/li>\n <li><strong>Bipolar disorder II :<\/strong> major depressive episodes + hypomanic episodes (\u22654 days) - always check for a history of hypomania and bipolar family history before starting an antidepressant alone (risk of manic drift); use the MDQ (Mood Disorder Questionnaire) for screening purposes<\/li>\n <li><strong>Medical causes to be systematically excluded:<\/strong> TSH (hypothyroidism); CBC + ferritin (iron-deficiency anemia); blood glucose + HbA1c (diabetes); liver function tests (chronic hepatitis C); vitamin D 25-OH; 24h urinary cortisol or dexamethasone braking (Cushing's disease); blood calcium (hyperparathyroidism); total testosterone in men (hypogonadism).<\/li>\n <li><strong>Personality disorder:<\/strong> chronic depressive features may be difficult to distinguish from borderline (emotional instability), avoidant (social withdrawal) or depressive disorder (constitutional pessimism) - frequent comorbidity (20-40 % of dysthymics); in-depth psychological assessment is sometimes required<\/li>\n <li><strong>Assessment tools :<\/strong> PHQ-9 (score \u226510 = moderate to severe depression - sensitivity 88 % for EDC); PHQ-2 (rapid screening 2 items); MDQ (bipolar screening); GAD-7 (very frequent comorbid anxiety); Cornell scale (elderly)<\/li>\n <\/ul>\n\n <h2>Treatments<\/h2>\n <table class=\"co-table\">\n <colgroup><col style=\"width:200px;\"><col style=\"width:42%;\"><col><\/colgroup>\n <thead>\n <tr><th>Treatment<\/th><th>Mechanism, dosage and indication<\/th><th>Effectiveness, duration and precautions<\/th><\/tr>\n <\/thead>\n <tbody>\n <tr>\n <td>SSRIS<br><small style=\"font-weight:400;color:#7a8fa0;\">1st-line pharmacology<\/small><\/td>\n <td>Serotonin transporter (SERT) blockade \u2192 increased synaptic availability of 5-HT \u2192 progressive neuroplastic effects (BDNF - HPA axis); sertraline (Zoloft) 50 mg\/day \u2192 100-200 mg\/day: 1st line recommended (favorable CYP interaction profile); escitalopram (Cipralex) 10 mg\/day \u2192 20 mg\/day : well tolerated, low CYP interactions; fluoxetine (Prozac) 20 mg\/day \u2192 40-60 mg\/day: long half-life (14 days for norfluoxetine \u2192 advantage if irregular adherence); paroxetine 20-40 mg\/day: effective but anticholinergic + CYP2D6 inhibitor; citalopram 20-40 mg\/day: limit to 40 mg\/d (QTc) - 20 mg\/d if >60 years old<\/td>\n <td>Onset of action: 2-4 weeks for first effects, 6-8 weeks for full effect - explain this delay to the patient to prevent early discontinuation; NNT \u2248 4.5 for response vs placebo (Lima 2003 meta-analysis - Cochrane); minimum recommended duration: 2 years (CANMAT 2016) due to chronic nature; sexual dysfunction 30-40 % (inform patient); withdrawal syndrome on discontinuation (especially paroxetine) \u2192 mandatory gradual taper over \u22654 weeks<\/td>\n <\/tr>\n <tr>\n <td>IRSNa<br><small style=\"font-weight:400;color:#7a8fa0;\">1st line - anxiety or pain comorbidity<\/small><\/td>\n <td>SERT + NET (noradrenaline) blockade \u2192 dual serotonergic + noradrenergic action; venlafaxine (Effexor XR) 37.5-75 mg\/day \u2192 150-225 mg\/day (significant noradrenergic action only >150 mg\/day); duloxetine (Cymbalta) 30 mg\/day \u2192 60-120 mg\/day : advantage if concomitant neuropathic pain or fibromyalgia (formal indication); desvenlafaxine (Pristiq) 50 mg\/day: fewer CYP2D6 interactions<\/td>\n <td>Efficacy in dysthymia comparable to SSRIs (CANMAT); blood pressure monitoring with high-dose venlafaxine (dose-dependent hypertension - monthly BP if >150 mg\/day); severe withdrawal syndrome on abrupt discontinuation of venlafaxine \u2192 decrease over several weeks mandatory; duloxetine: frequent nausea at start of treatment (take in the evening with a meal); hepatic monitoring if alcohol consumption.<\/td>\n <\/tr>\n <tr>\n <td>Psychotherapy - CBT, TIP, CBASP<br><small style=\"font-weight:400;color:#7a8fa0;\">1st line - in combination with pharmacotherapy<\/small><\/td>\n <td>CBT (cognitive-behavioural therapy): restructuring of chronic negative cognitive patterns (automatic pessimistic thoughts, cognitive distortions) + behavioural activation - 12-20 weekly sessions; IPT (interpersonal therapy): focus on chronic relationship difficulties - 16 sessions; CBASP (Cognitive Behavioral Analysis System of Psychotherapy - McCullough): psychotherapy developed specifically for chronic depression - situational analysis and interpersonal consequences - superior to standard CBT in some chronic depression trials.<\/td>\n <td>Antidepressant + psychotherapy combination superior to each modality alone in chronic depression (NNT \u2248 3.2 - Cuijpers 2010 meta-analysis - JAMA); access to psychotherapy in Quebec: significant delays in the public network (CLSC, GMF) - some GMF-U and affiliated clinics offer integrated psychology services; RAMQ reimbursement under certain PASM programs; ACT and MBCT (mindfulness): emerging data in dysthymia for reduction of ruminations and experiential avoidance<\/td>\n <\/tr>\n <tr>\n <td>2nd-line antidepressants and augmentation strategies<br><small style=\"font-weight:400;color:#7a8fa0;\">Resistance or intolerance to SSRIs\/ASNRIs<\/small><\/td>\n <td>Mirtazapine (Remeron) 15-45 mg\/day at bedtime: presynaptic \u03b12 antagonist + 5-HT2\/5-HT3 + H1 \u2192 sedation + increased appetite - useful if insomnia + weight loss + anxiety; bupropion (Wellbutrin XL) 150-300 mg\/day: NE + DA reuptake inhibitor \u2192 activating if fatigue + apathy + SSRI-induced sexual dysfunction - CI epilepsy, TCA, alcohol withdrawal; agomelatine (Valdoxan) 25-50 mg\/day: MT1\/MT2 agonist + 5-HT2C antagonist \u2192 normalization of circadian rhythm - monthly liver monitoring for first 6 months; augmentation with lithium (0.4-0.8 mmol\/L) + quetiapine XR (Seroquel 50-300 mg\/night) + aripiprazole (Abilify 5-15 mg\/day) if partial response at optimal dose<\/td>\n <td>Add-on strategy indicated if partial response after 8 weeks at optimal dose of an SSRI\/SNRI; lithium: recommendation level 1 (CANMAT 2016) - lithiaemia + TSH + creatinine + calcaemia to be monitored; quetiapine: formal indication in unipolar depression (El-Khalili 2010 meta-analysis) - metabolic monitoring (blood sugar, cholesterol, weight); aripiprazole: augmentation if partial response to DAs; ketamine\/esketamine (Spravato): reserved for resistant depression in specialized setting - not approved in pure dysthymia in Canada<\/td>\n <\/tr>\n <tr>\n <td>Healthy living and complementary interventions<br><small style=\"font-weight:400;color:#7a8fa0;\">Adjuvants - proven effectiveness<\/small><\/td>\n <td>Aerobic physical exercise: 150 min\/week of moderate intensity (brisk walking, cycling, swimming) \u2192 increase BDNF, reduce cortisol, improve prefrontal neuroplasticity - CANMAT 2016 recommendation (level 1); light therapy: 10,000 lux for 30 min in the morning \u2192 efficacy in seasonal and non-seasonal dysthymia (Lam 2016 meta-analysis - JAMA Psychiatry) - available in pharmacies or for hire; sleep hygiene: regular schedules, avoid screens before bedtime, ICT (cognitive therapy for insomnia) if associated chronic insomnia; alcohol reduction (CNS depressant - frequent self-medication but worsens dysthymia in the medium term)<\/td>\n <td>Physical exercise is often under-prescribed despite its proven efficacy (MDS -0.66 vs control - Schuch 2016 - American Journal of Psychiatry) - written prescription for physical activity (PEP) improves adherence; light therapy: relative contraindication in bipolar disorder (risk of manic turn - use cautiously with supervision); omega-3s (EPA 1-2 g\/day): modest efficacy as adjunct to pharmacotherapy (CANMAT level 2 - Grosso 2014 meta-analysis) - to be proposed if reluctant to take medication or as a supplement<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n\n <div class=\"co-infobox\">\n <span class=\"ico\">\u2139\ufe0f<\/span>\n <span>Visit <strong>double depression<\/strong> - superimposing a characterized depressive episode on a pre-existing dysthymia - is observed in 40-75 % of dysthymic people over the course of their lives. It manifests as a sudden worsening of the chronic baseline mood, with the onset of more intense symptoms (profound anhedonia, psychomotor slowing, suicidal ideation) exceeding the criteria for dysthymia alone. Double depression is associated with a less complete response to antidepressants (frequent partial remission - return to baseline dysthymic level without complete recovery) and a higher rate of recurrence. A <strong>complete remission<\/strong> (return to euthymia) must always be the therapeutic goal, and not simply a return to dysthymic levels. Long-term follow-up (\u22652 years of pharmacological treatment + psychotherapy) is essential to prevent relapse.<\/span>\n <\/div>\n\n <div class=\"co-urgence\">\n <div class=\"co-urgence-titre\">Suicidal ideation - Help available<\/div>\n <p>Although low-grade, dysthymia is associated with a significant suicidal risk - especially in the case of double depression or in the presence of co-morbidities (personality disorder, substance abuse, social isolation). If you are experiencing suicidal thoughts or thoughts of death, talk to your doctor or a mental health professional.<\/p>\n <p><strong>Quebec suicide prevention line: 1 866 APPELLE (277-3553)<\/strong> - available 24\/7; ; <strong>Crise Montr\u00e9al: 514 890-6000<\/strong> ; <strong>Kids Help Phone: 1 800 668-6868<\/strong> (under 29 years of age). In case of immediate danger to yourself: call <strong>911<\/strong> or go to the nearest emergency room.<\/p>\n <\/div>\n\n <h2>Consult at Clinique Omicron<\/h2>\n <p>Clinique Omicron's physicians provide initial screening and management of dysthymia - structured clinical evaluation (PHQ-9), workup to rule out medical causes (TSH, CBC, metabolic workup), initiation of first-line pharmacotherapy, referral to psychology or psychiatry, and longitudinal follow-up of treatment. Telemedicine is available for follow-up mental health consultations at our points of service in Quebec. To book an appointment, visit <a href=\"https:\/\/cliniqueomicron.ca\">cliniqueomicron.ca<\/a>.<\/p>\n\n <p class=\"co-disclaimer\">The content of this page is provided for informational purposes only and does not replace the advice of a qualified healthcare professional. If you experience persistent depressive symptoms, consult your physician or a mental health professional. In the event of a crisis, contact available resources immediately.<\/p>\n<\/div>\n<\/body>\n<\/html>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Dysthymie (trouble d\u00e9pressif persistant) : sympt\u00f4mes et traitement | Clinique Omicron Psychiatrie & Psychologie & M\u00e9decine de famille Dysthymie (trouble d\u00e9pressif persistant) La dysthymie \u2014 officiellement renomm\u00e9e trouble d\u00e9pressif persistant (TDP) dans le DSM-5 (2013) et la CIM-11 (2022) \u2014 est un trouble de l’humeur caract\u00e9ris\u00e9 par une humeur d\u00e9pressive chronique de bas grade, pr\u00e9sente… <a href=\"https:\/\/cliniqueomicron.ca\/en\/dysthymie\/\" rel=\"bookmark\">Read More \"<span class=\"screen-reader-text\">Dysthymia (persistent depressive disorder): symptoms and treatment | Clinique Omicron<\/span><\/a><\/p>","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"off","neve_meta_content_width":100,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"_metasync_otto_title":"Dysthymie (trouble d\u00e9pressif persistant) | Omicron","_metasync_otto_description":"Dysthymie : Clinique Omicron \u00e0 Brossard propose un traitement efficace avec psychoth\u00e9rapie et m\u00e9dicaments. Am\u00e9liorez votre quotidien. Contactez-nous.","_metasync_otto_keywords":"","_metasync_otto_og_title":"Dysthymie (trouble d\u00e9pressif | Brossard | Clinique Omicron","_metasync_otto_og_description":"La dysthymie ou trouble d\u00e9pressif persistant est une d\u00e9pression chronique de bas grade durant plus de 2 ans. Crit\u00e8res DSM-5, antid\u00e9presseurs, psychoth\u00e9rapie...","_metasync_otto_twitter_title":"Dysthymie (trouble d\u00e9pressif | Brossard | Clinique Omicron","_metasync_otto_twitter_description":"La dysthymie ou trouble d\u00e9pressif persistant est une d\u00e9pression chronique de bas grade durant plus de 2 ans. Crit\u00e8res DSM-5, antid\u00e9presseurs, psychoth\u00e9rapie...","rank_math_title":"","rank_math_description":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_aioseo_title":"Dysthymie (trouble d\u00e9pressif persistant) : sympt\u00f4mes et traitement | Clinique Omicron","_aioseo_description":"La dysthymie ou trouble d\u00e9pressif persistant est une d\u00e9pression chronique de bas grade durant plus de 2 ans. Crit\u00e8res DSM-5, antid\u00e9presseurs, psychoth\u00e9rapie et prise en charge au Qu\u00e9bec.","_metasync_seo_title":"","_metasync_seo_desc":"","_metasync_breadcrumb_title":"","_metasync_primary_category":0,"_metasync_primary_product_cat":0,"_metasync_otto_disabled":"","_metasync_hreflang":"","_metasync_plugin_sync_ts":"{\"aioseo\":\"2026-05-04T21:54:40+00:00\"}","_metasync_robots_advanced":"","footnotes":""},"class_list":["post-24524","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/pages\/24524","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/comments?post=24524"}],"version-history":[{"count":4,"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/pages\/24524\/revisions"}],"predecessor-version":[{"id":28480,"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/pages\/24524\/revisions\/28480"}],"wp:attachment":[{"href":"https:\/\/cliniqueomicron.ca\/en\/wp-json\/wp\/v2\/media?parent=24524"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}